Liquid Biopsy Cancer Screening (LucenceINSIGHT & SPOT-MAS)

Wonderhealth Screeners offers two complementary liquid biopsy platforms for multi-cancer early detection (MCED), both using next-generation sequencing to analyse circulating tumour DNA (ctDNA) shed by cancer cells into the bloodstream — enabling detection of cancer signals years before symptoms appear.

The SPOT-MAS 10 test (SGD 785, GST-inclusive) screens for ten of the most prevalent cancers in Singapore and Southeast Asia: lung (small cell and non-small cell), colorectal, stomach, liver and biliary tract, head and neck, oesophagus, pancreas, breast, ovary, and uterus. Clinical validation across more than 11,000 participants demonstrated 78.1% sensitivity, 99.8% specificity, and 84% accuracy in identifying the tissue of origin — enabling guided…

The LucenceINSIGHT platform offers a tiered range of packages based on the number of cancer types screened. The entry-level LucenceINSIGHT 5 (SGD 950) covers five major cancers, while gender-specific packages — Women's 7 (SGD 1,250), Women's 12 (SGD 1,935), and Men's 12 (SGD 1,935) — target the most relevant cancer types for each demographic. The flagship LucenceINSIGHT 50 (SGD 3,650) screens for up to 50 distinct cancer types in a single blood draw,…